利奈唑胺治疗耐多药肺结核临床疗效观察  

Clinical efficacy of linezolid in treatment of multi-drug resistant pulmonary tuberculosis

作　　者：刘智[1] 杨梁梓[1] 傅佳鹏[1] 刘志超[1] 柯学[1] 李剑[1] 傅向东[1] 李国保[1] 

机构地区：[1]深圳市第三人民医院,广东深圳518112

出　　处：《临床肺科杂志》2017年第7期1173-1176,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察利奈唑胺在治疗耐多药肺结核(MDR-TB)的临床疗效和不良反应。方法将46例耐多药肺结核患者随机分为治疗组22例,对照组24例;治疗方案:治疗组以利奈唑胺为主,联合阿米卡星、吡嗪酰胺、丙硫异烟胺、乙胺丁醇、左氧氟沙星,对照组为阿米卡星、吡嗪酰胺、丙硫异烟胺、乙胺丁醇、左氧氟沙星,所有病例疗程均为24个月。结果至疗程结束,治疗组治疗成功率94.7%,对照组为66.7%,两组差异有统计学意义(P<0.05);治疗组病灶吸收(显吸+吸收)率为100%,对照组为71.4%,两组差异有统计学意义(P<0.05);不良反应率治疗组(78.95%)要高于对照组(33.33%),两组差异有统计学意义(P<0.01)。结论利奈唑胺用于治疗耐多药结核时痰菌转阴率高,不良反应可控,不失为治疗耐多药结核的良药,给广大耐多药患者带来希望。Objective To evaluate the clinical therapeutic effect and adverse reaction of linezolid in treat-ment of multi-drug resistant pulmonary tuberculosis （MDR-TB） patients. Methods 46 MDR-TB patients were divided randomly into the study group （n = 2 2 ） and the control group （ n = 24） . The study group was treated with linezolid mainly combined with amikacin, pyrazinamide, protionamide, ethambutol and levofloxacin for 24 months, and the control group was given amikacin, pyrazinamide, protionamide, ethambutol and levofloxacin for 24 months. Results At the end of treatment, the treatment success rate was 66. 7% in the control group and 94. 7% in the treat-ment group （P 〈0. 05）. Lesions absorption rate （marked absorption and absorption） were 71. 1% in the control and 100% in the treatment group （ P 〈 0. 05 ）. The incidence of adverse reactions was 33. 33% in the control group and 78. 95% in the treatment group （ P 〈 0. 01） . Conclusion Linezolid will bring more benefits for MDR-TB patients by improving the sputum negative conversion rate, though some slight adverse reaction may unexpected happened but also be prevented.

关 键 词：利奈唑胺 耐多药肺结核 临床疗效 不良反应 

分 类 号：R521[医药卫生—内科学]